Helix BioMedix is a biotechnology company dedicated to the discovery and early-stage development of innovative peptide-based therapeutics, with a primary focus on dermatology and skin health. We leverage our proprietary peptide technology and scientific expertise to explore novel approaches for addressing rare and underserved dermatologic conditions.

Our lead program focuses on Xeroderma Pigmentosum, a rare disease caused by defective DNA repair mechanisms. Guided by research and preclinical development, we aim to advance scientific understanding and create meaningful solutions that may improve the quality of life for affected patients.

In addition to our therapeutic work, Helix BioMedix maintains a legacy peptide platform that supports select applications in personal care and related markets. As we continue to grow, our mission remains clear: to transform peptide science into life-enhancing innovations built on safety, efficacy, and scientific integrity.